Expertise in
9
conditions

Jianming M. Xu

No. 8 East Street, 
Fengtai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
No. 8 East Street, 
Fengtai, CN 

Overview

Jianming Xu practices practicing medicine in Fengtai, China.

Xu is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Esophageal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Hepato-Pancreato-Biliary Surgery, and Osteotomy.

They are actively involved in clinical research, co-authoring 383 peer reviewed articles and participating in 1 clinical trial.

Locations

No. 8 East Street, Fengtai, 100071, China
Other Locations
28 Fuxing Road, Beijing, 100039, China
No. 1 Lijiang Road, Suzhou, 215153, China
Jiangsu Key Laboratory For Eco Agricultural Biotechnology Around Hongze Lake, Chaigoubu, 223300, China
Road 8, Dong Street, Fengtai, China
#79, Qingchun Road, Hangzhou, 310003, China
No. 8 East St, Fengtai, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement
An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement
Enrollment Status: Recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drug: HMPL-453
Study Phase: Phase 2/Phase 3

383 Total Publications

Rat somatic genome editing enables ER+ breast cancer modeling.
Rat somatic genome editing enables ER+ breast cancer modeling.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 22, 2026

Frequently Asked Questions about Jianming M. Xu

Is Jianming M. Xu a top-rated expert for Esophageal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jianming M. Xu is classified as an Distinguished expert for Esophageal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jianming M. Xu participate in research or clinical trials?

Yes. Jianming M. Xu has published 383 articles and abstracts on conditions like Esophageal Cancer. You can view a list of Jianming M. Xu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xu's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile